FGFR2 inhibitors for the treatment of cholangiocarcinoma

摘要

Evaluating a biological sample from the patient for the presence of at least one FGFR mutant comprising at least FGFR2 SNP C383R; And treating a patient with a FGFR inhibitor when at least one FGFR mutant comprising at least FGFR2 SNP C383R is present in the sample, disclosed herein is a method of treating cholangiocarcinoma in a patient.